Evidence map›Paper›PMID 41711446›Full record

ArticleAntimicrobial agents and chemotherapy2026

The novel second-generation triterpenoid SCY-247 maintains

Nathan P Wiederhold, Laura K Najvar, Rosie Jaramillo, Marcos Olivo, Hoja P Patterson, Thomas F Patterson

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nathan P WiederholdUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID 0000-0002-2225-5122
Laura K NajvarUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Rosie JaramilloUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Marcos OlivoUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Hoja P PattersonUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Thomas F PattersonUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID 0000-0002-9513-7127

Funding

Task A29: In vitro screening for antifungal activity against fungal disease pathogens75N93019D00022 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI PATTERSON, THOMAS · 2019 to 2025
$930k
NIH HHS 75N93019D00022NIH HHS 75N93023F00001Scynexis
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antifungal AgentsCandida glabrataTriterpenesAnimalsCandidiasisCaspofunginDrug Resistance, FungalEchinocandinsFemaleFluconazoleLipopeptidesLungMiceMicrobial Sensitivity TestsAntifungal AgentsCaspofunginEchinocandinsFluconazoleLipopeptidesTriterpenesCandida glabrataechinocandin resistanceinvasive candidiasismurine modelSCY-247triterpenoid

Identifiers

PMID41711446
PMCPMC13041391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.